Short answer
Praxis Precision Medicines, Inc. (PRAX) filed an 8-K current report with the SEC on April 6, 2026 reporting Item 8.01 (Other Events). Elsunersen achieved 77% placebo-adjusted seizure reduction, with statistical significance at p=0.015.
Praxis Precision Medicines, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- Elsunersen achieved 77% placebo-adjusted seizure reduction, with statistical significance at p=0.015
- 57% of patients experienced at least 28 days of seizure freedom
- Benefits sustained up to one year, with 100% of treated patients showing functional improvements
- Favorable safety profile: no drug-related serious adverse events, discontinuations, or neuroinflammation signals up to 8 mg
- FDA priority review accepted for relutrigine, with September 27, 2026 PDUFA action date
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Praxis Precision Medicines, Inc. 8-K filings
Get the next PRAX 8-K as it lands
Follow PRAX for push alerts, or ask the research agent what this filing means.